Abstract Triple-negative breast cancer (TNBC) is a subtype of breast cancer associated with a poor prognosis; conventional treatments provide limited durable benefit, and resistance commonly develops. The introduction of immune checkpoint inhibitors (ICIs) has expanded treatment options for TNBC; however, ICI monotherapy has demonstrated limited efficacy, particularly in patients with advanced disease.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Chenming
Contact Chenming, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack